Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380078996> ?p ?o ?g. }
- W4380078996 endingPage "411" @default.
- W4380078996 startingPage "410" @default.
- W4380078996 abstract "Background: Real-life studies of moderate size have shown satisfactory but less impressive results compared with the original R-da-EPOCH publication for PMLBCL. However, large studies are needed efficacy and toxicity of R-da-EPOCH, the use of radiotherapy (RT) and significance of the compliance with the strict dose escalation strategy of the protocol. Aim: To assess the clinical outcomes after R-da-EPOCH, the use of RT and protocol compliance in a multinational real-life setting. Patients and Methods: 274 patients (pts) were enrolled from 18 Greek, Israeli, Turkish, Saudi, Cypriot and Maltese centers (n = 143, 66, 34, 22, 5 and 4 pts respectively). Consolidative RT was given at the treating physician’s discretion and was highly affected by PET/CT results. Results: The median age of the pts was 33 years (16–63), 62% were females, 38% had B-symptoms, 33% extranodal involvement (E or stage IV), 18% PS ≥ 2, 83% elevated LDH (34% highly elevated ≥2x normal). RT was spared in the overwhelming majority of responders. The 5-year Freedom From Progression (FFP) was 85%. However, 5 pts developed therapy-related (t-)AML at 10.5–24 months from treatment initiation, while in 1st remission, and one Hodgkin lymphoma. The 5-year overall survival (OS) was 91% with 20 disease-related deaths (1 toxic). Protocol violations were common (54% of 245 patients with available data so far), mainly consisting of insufficient dose escalation despite the absence of prohibitive toxicity. Among 258 pts with available data, 60% reached level ≥3 and 30% ≥4 (73% and 44% among those with strict protocol adherence). The 5-year FFP was 89% versus 83% for pts with strict protocol adherence or not (p = 0.19); 5-year OS was not also different (91% vs. 92%, p = 0.74). FFP and OS did not differ according to the final level reached (≥3 or ≥4). A more detailed analysis of outcome according to the degree of protocol violations is currently ongoing. Pts with both risk factors according to the prognostic systems including any extranodal involvement and highly elevated LDH (≥2x) or bulk had inferior outcomes but still better than those achieved by R-CHOP in high-risk pts. Conclusions/Discussion: In the largest series reported so far for R-da-EPOCH in PMLBCL, FFP appeared somewhat but not impressively better than the expected with R-CHOP, but this was achieved with the safe omission of RT was in >85% of responders. OS was >90%. The appearance of 5 cases of t-AML among 274 pts is worrisome. Significant dose-escalation violations were recorded in the real-life; their impact on outcomes appears to be modest and is further evaluated. A final analysis on 290–300 pts will be presented at the Meeting. Keyword: Aggressive B-cell non-Hodgkin lymphoma No conflicts of interests pertinent to the abstract." @default.
- W4380078996 created "2023-06-10" @default.
- W4380078996 creator A5001887761 @default.
- W4380078996 creator A5004992368 @default.
- W4380078996 creator A5005309444 @default.
- W4380078996 creator A5006807333 @default.
- W4380078996 creator A5011106924 @default.
- W4380078996 creator A5012003196 @default.
- W4380078996 creator A5013890206 @default.
- W4380078996 creator A5019338305 @default.
- W4380078996 creator A5023008706 @default.
- W4380078996 creator A5023512060 @default.
- W4380078996 creator A5024960041 @default.
- W4380078996 creator A5025358969 @default.
- W4380078996 creator A5026191307 @default.
- W4380078996 creator A5028690834 @default.
- W4380078996 creator A5030399738 @default.
- W4380078996 creator A5031256616 @default.
- W4380078996 creator A5031397350 @default.
- W4380078996 creator A5032351167 @default.
- W4380078996 creator A5037546722 @default.
- W4380078996 creator A5041125510 @default.
- W4380078996 creator A5041333987 @default.
- W4380078996 creator A5047967246 @default.
- W4380078996 creator A5049817881 @default.
- W4380078996 creator A5052212457 @default.
- W4380078996 creator A5052426158 @default.
- W4380078996 creator A5052579016 @default.
- W4380078996 creator A5054152992 @default.
- W4380078996 creator A5059876271 @default.
- W4380078996 creator A5060612356 @default.
- W4380078996 creator A5065368922 @default.
- W4380078996 creator A5070086014 @default.
- W4380078996 creator A5070642290 @default.
- W4380078996 creator A5071470792 @default.
- W4380078996 creator A5072468961 @default.
- W4380078996 creator A5074130084 @default.
- W4380078996 creator A5079303968 @default.
- W4380078996 creator A5079323263 @default.
- W4380078996 creator A5083879904 @default.
- W4380078996 creator A5086594420 @default.
- W4380078996 creator A5086608069 @default.
- W4380078996 creator A5092127574 @default.
- W4380078996 date "2023-06-01" @default.
- W4380078996 modified "2023-10-18" @default.
- W4380078996 title "REAL‐LIFE EXPERIENCE WITH RITUXIMAB‐DOSE‐ADJUSTED EPOCH (R‐da‐EPOCH) IN PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (PMLBCL): A MULTINATIONAL ANALYSIS OF 274 PATIENTS" @default.
- W4380078996 doi "https://doi.org/10.1002/hon.3164_301" @default.
- W4380078996 hasPublicationYear "2023" @default.
- W4380078996 type Work @default.
- W4380078996 citedByCount "0" @default.
- W4380078996 crossrefType "journal-article" @default.
- W4380078996 hasAuthorship W4380078996A5001887761 @default.
- W4380078996 hasAuthorship W4380078996A5004992368 @default.
- W4380078996 hasAuthorship W4380078996A5005309444 @default.
- W4380078996 hasAuthorship W4380078996A5006807333 @default.
- W4380078996 hasAuthorship W4380078996A5011106924 @default.
- W4380078996 hasAuthorship W4380078996A5012003196 @default.
- W4380078996 hasAuthorship W4380078996A5013890206 @default.
- W4380078996 hasAuthorship W4380078996A5019338305 @default.
- W4380078996 hasAuthorship W4380078996A5023008706 @default.
- W4380078996 hasAuthorship W4380078996A5023512060 @default.
- W4380078996 hasAuthorship W4380078996A5024960041 @default.
- W4380078996 hasAuthorship W4380078996A5025358969 @default.
- W4380078996 hasAuthorship W4380078996A5026191307 @default.
- W4380078996 hasAuthorship W4380078996A5028690834 @default.
- W4380078996 hasAuthorship W4380078996A5030399738 @default.
- W4380078996 hasAuthorship W4380078996A5031256616 @default.
- W4380078996 hasAuthorship W4380078996A5031397350 @default.
- W4380078996 hasAuthorship W4380078996A5032351167 @default.
- W4380078996 hasAuthorship W4380078996A5037546722 @default.
- W4380078996 hasAuthorship W4380078996A5041125510 @default.
- W4380078996 hasAuthorship W4380078996A5041333987 @default.
- W4380078996 hasAuthorship W4380078996A5047967246 @default.
- W4380078996 hasAuthorship W4380078996A5049817881 @default.
- W4380078996 hasAuthorship W4380078996A5052212457 @default.
- W4380078996 hasAuthorship W4380078996A5052426158 @default.
- W4380078996 hasAuthorship W4380078996A5052579016 @default.
- W4380078996 hasAuthorship W4380078996A5054152992 @default.
- W4380078996 hasAuthorship W4380078996A5059876271 @default.
- W4380078996 hasAuthorship W4380078996A5060612356 @default.
- W4380078996 hasAuthorship W4380078996A5065368922 @default.
- W4380078996 hasAuthorship W4380078996A5070086014 @default.
- W4380078996 hasAuthorship W4380078996A5070642290 @default.
- W4380078996 hasAuthorship W4380078996A5071470792 @default.
- W4380078996 hasAuthorship W4380078996A5072468961 @default.
- W4380078996 hasAuthorship W4380078996A5074130084 @default.
- W4380078996 hasAuthorship W4380078996A5079303968 @default.
- W4380078996 hasAuthorship W4380078996A5079323263 @default.
- W4380078996 hasAuthorship W4380078996A5083879904 @default.
- W4380078996 hasAuthorship W4380078996A5086594420 @default.
- W4380078996 hasAuthorship W4380078996A5086608069 @default.
- W4380078996 hasAuthorship W4380078996A5092127574 @default.
- W4380078996 hasBestOaLocation W43800789961 @default.
- W4380078996 hasConcept C121332964 @default.
- W4380078996 hasConcept C126322002 @default.
- W4380078996 hasConcept C1276947 @default.
- W4380078996 hasConcept C141071460 @default.
- W4380078996 hasConcept C150846664 @default.